RFPs Archives • AMR.Solutions

Start your engines! BARDA antibiotic procurement RFP / CARB-X 2019 funding round webinar

Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP, BARDA plans to support the procurement of antibiotic(s), which will either be delivered to the ASPR/SNS or maintained as VMI, using Project BioShield (PBS) funds. “PBS funds will also support

9 May 2019 No Comments

Upcoming BARDA RFP to acquire antibiotic(s) for biothreat indications!

Dear All: Ready, set, (get ready to) go! I just today learned of this really important US government pre-solicitation notice (lightly reformatted excerpt follows, see here for the whole thing): “The Government seeks an FDA-approved antibiotic(s) for a biothreat indication (Y. pestis, B. anthracis, F. tularensis, B. mallei and/or B. pseudomallei) for delivery to the Office of the Assistant Secretary for Preparedness and Response

16 April 2019 No Comments

FORWARD Act, PREVENT Act, new NIAID RFP!

Dear All, Our US government colleagues have been busy! Three things back-to-back: First, the FORWARD Act (Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2022”) was introduced in the US Senate on 13 Jan 2021 as S.3498 by Sens. Kelly, Sinema, and Feinstein. You’ve got to admire the acronymics! The Senate bill is the

27 January 2022 No Comments

RFP: Climate-Sensitive Infectious Disease Modelling

Dear All, And now for something really different! With the recent GRAM report (20 Jan 2022 newsletter) showing that AMR is linked to more deaths that HIV or malaria (#AMRSOS! Andrew Jack and FT team have some great graphics for this … check them out!), we now have an absolutely fascinating call from Wellcome Trust for

2 February 2022 No Comments

RFP: Support for creating Antimicrobial Stewardship Centers of Excellence

Dear All, I wrote in a 26 Oct 2021 newsletter about an RFP focused on Antimicrobial Stewardship (AMS) activities to address health inequities arising from socioeconomic disparities. The core concept is that AMR disproportionally impacts underserved patient communities world-wide. Racial minorities, ethnic minorities, and elderly patients in both developed and developing economies are all at risk. Building on

31 January 2022 No Comments

PAR Foundation grants: Early career support, prevention of AMR in the elderly

Dear All, The Stockholm-based PAR Foundation (aka, the Foundation to Prevent Antibiotic Resistance) has announced two groups of grant opportunities. First, early career grants of up to ~€30k are available to support 1-year projects on prevention of antibiotic resistance. What: “The aim of this call is to improve the ability and interest of promising early-career individuals

23 January 2022 No Comments

FDA posts 4 RFPs! MIC breakpoints, PRO for ABPA, dosing in obesity/CRRT!

Dear All, Whew … still catching up after all the activities of World Antimicrobial Awareness Week (WAAW)! More to follow on some of that great content, but for today we have the news that FDA has posted 4 RFPs! All have due dates of 21 Jan 2022: Optimizing dosing strategies for obese patients and in continuous

2 December 2021 No Comments

BARDA and NIAID RFPs addressing bacterial, fungal, and viral threats

Dear All, When it rains, it pours … and sometimes in a good way! Today saw the release of requests for proposals by NIAID and BARDA for therapeutics (antibacterial, antifungal, antiviral), vaccines (again, all 3 areas), and diagnostics. It’s an impressive list of opportunities that covers both biothreat pathogens as well as NIAID’s list of

20 January 2022 No Comments

RFP: Gender inequality in AMR (with a focus on sub-Saharan Africa)

Dear All, Continuing with the theme of socio-economic inequality and AMR that we discussed in prior newsletters (31 Jan 2022, “RFP: Support For Creating Antimicrobial Stewardship Centers Of Excellence” and 26 Oct 2021, “$50-100k Grants To Address Socioeconomic Outcome Disparities Due To AMR-Related Factors”), we today have an RFP on gender and AMR from the

13 February 2022 No Comments

WHO pipeline review; JPIAMR call on “Disrupting drug resistance using innovative design”

Dear All, First up, we have an update to WHO’s review of the clinical antibacterial pipeline. The review by Butler et al. in AAC (and for transparency, know that I am a co-author) covers both traditional and non-traditional products. It found that as of 30 June 2021: There were 76 antibacterial agents in clinical development

17 January 2022 No Comments

AMR.Solutions

RFPs